Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial). Am J Cardiol 2005 Feb 15;95(4):529-32

Date

02/08/2005

Pubmed ID

15695147

DOI

10.1016/j.amjcard.2004.10.026

Scopus ID

2-s2.0-13844296683 (requires institutional sign-in at Scopus site)   29 Citations

Abstract

The comparison of treatment effect and co-morbidity between the genders in the Valsartan Heart Failure Trial showed equal benefit of treatment in men and women. Co-morbidities, such as diabetes and coronary artery disease, increased nonfatal cardiac morbidity more in women than in men.

Author List

Majahalme SK, Baruch L, Aknay N, Goedel-Meinen L, Hofmann M, Hester A, Prescott MF, Feliciano N, Val-HeFT Study Investigators

Author

Silja Majahalme MD, PhD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Comorbidity
Coronary Artery Disease
Diabetes Mellitus
Double-Blind Method
Female
Heart Failure
Hospitalization
Humans
Male
Middle Aged
Severity of Illness Index
Sex Distribution
Tetrazoles
United States
Valine
Valsartan